MAPT and early-onset autosomal dominant Alzheimer disease: There is a need for a therapeutic drug that can fight against the culprit enzymes of Alzheimer’s disease (AD), which is pathologically characterized by the extracellular accumulation of aberrant amyloid-peptide peptides into plaques, the hyperphosphorylation of the microtubule-associated protein Tau resulting in the development of neurofibrillary tangles (NFTs) and neuroinflammation [40].